Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies

Journal of Immunological Methods

Volumn 318, Issue 1-2, 2007, Pages 65-74

  Shen, Juqun ^a   Vil, Marie Danielle ^a   Jimenez, Xenia ^a   Zhang, Haifan ^a   Iacolina, Michelle ^a   Mangalampalli, Venkat ^a   Balderes, Paul ^a   Ludwig, Dale L ^a   Zhu, Zhenping ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antibody engineering; Bispecific antibody; Dual targeting; PDGFR ; PDGFR ; Single domain antibody

Indexed keywords

BISPECIFIC ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN A; RECEPTOR PROTEIN; SINGLE DOMAIN ANTIBODY; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL CELL; ANTIBODY ENGINEERING; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; GENE CONSTRUCT; GENETIC RECOMBINATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN VARIABLE REGION; KINETICS; MICE; MODELS, MOLECULAR; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

MAMMALIA;

EID: 33845884563     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2006.09.020     Document Type: Article

References (32)

1. Atwell S., Ridgway J.B., Wells J.A., and Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J. Mol. Biol. 270 (1997) 26-35
2. Baeuerle P.A., Kufer P., and Lutterbuse R. Bispecific antibodies for polyclonal T-cell engagement. Curr. Opin. Mol. Ther. 5 (2003) 413-419
3. Binz H.K., and Pluckthun P. Engineered proteins as specific binding reagents. Curr. Opin. Biotechnol. 16 (2005) 459-469
4. Brennan M., Davison P.F., and Paulus H. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 229 (1985) 81-83
5. Cai X., and Garen A. A melanoma-specific VH antibody cloned from a fusion phage library of a vaccinated melanoma patient. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 6280-6285
6. Carter P. Bispecific human IgG by design. J. Immunol. Methods 248 (2001) 7-15
7. Carter P., Ridgway J., and Zhu Z. Toward the production of bispecific antibody fragments for clinical applications. J. Hematother. 4 (1995) 463-470
8. Chang C.H., Sharkey R.M., Rossi E.A., Karacay H., McBride W., Hansen H.J., Chatal J.F., Barbet J., and Goldenberg D.M. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol. Cancer Ther. 1 (2002) 553-563
9. Coloma M.J., and Morrison S.L. Design and production of novel tetravalent bispecific antibodies. Nat. Biotechnol. 15 (1997) 159-163
10. Hoet R.M., Cohen E.H., Kent R.B., Rookey K., Schoonbroodt S., Hogan S., Rem L., Frans N., Daukandt M., Pieters H., van Hegelsom R., Neer N.C., Nastri H.G., Rondon I.J., Leeds J.A., Hufton S.E., Huang L., Kashin I., Devlin M., Kuang G., Steukers M., Viswanathan M., Nixon A.E., Sexton D.J., Hoogenboom H.R., and Ladner R.C. Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat. Biotechnol. 23 (2005) 344-348
11. Holliger P., and Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23 (2005) 1126-1136
12. Holt L.J., Herring C., Jespers L.S., Woolven B.P., and Tomlinson I.M. Domain antibodies: proteins for therapy. Trends Biotechnol. 21 (2003) 484-490
13. Jendreyko N., Popkov M., Rader C., and Barbas III C.F. Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 8293-8298
14. Jimenez X., Lu D., Brennan L., Persaud K., Liu M., Miao H., Witte L., and Zhu Z. A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3. Mol. Cancer Ther. 4 (2005) 427-434
15. Kipriyanov S.M., and Le Gall F. Recent advances in the generation of bispecific antibodies for tumor immunotherapy. Curr. Opin. Drug Discov. Dev. 7 (2004) 233-242
16. Kipriyanov S.M., Moldenhauer G., Braunagel M., Reusch U., Cochlovius B., Le Gall F., Kouprianova O.A., Von der Lieth C.W., and Little M. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies. J. Mol. Biol. 330 (2003) 99-111
17. Kontermann R.E. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol. Sin. 26 (2005) 1-9
18. Lu D., Jimenez X., Zhang H., Wu Y., Bohlen P., Witte L., and Zhu Z. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. Cancer Res. 61 (2001) 7002-7008
19. Lu D., Jimenez X., Zhang H., Bohlen P., Witte L., and Zhu Z. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int. J. Cancer 97 (2002) 393-399
20. Lu D., Zhang H., Ludwig D., Persaud A., Jimenez X., Burtrum D., Balderes P., Liu M., Bohlen P., Witte L., and Zhu Z. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J. Biol. Chem. 279 (2004) 2856-2865
21. Lu D., Jimenez X., Witte L., and Zhu Z. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody. Biochem. Biophys. Res. Commun. 318 (2004) 507-513
22. Lu D., Zhang H., Koo H., Tonra J., Balderes P., Prewett M., Corcoran E., Mangalampalli V., Bassi R., Anselma D., Patel D., Kang X., Ludwig D.L., Witte L., and Zhu Z. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J. Biol. Chem. 280 (2005) 19665-19672
23. Lum L.G., and Davol P.A. Retargeting T cells and immune effector cells with bispecific antibodies. Cancer Chemother. Biol. Response Modif. 22 (2005) 273-291
24. Marvin J., and Zhu Z. Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol. Sin. 26 (2005) 649-658
25. Marvin J., and Zhu Z. Bispecific antibodies for dual-modality cancer therapy: killing two signaling cascades with one stone. Curr. Opin. Drug Discov. Dev. 9 (2006) 184-193
26. Merchant A.M., Zhu Z., Yuan J.Q., Goddard A., Adams C.W., Presta L.G., and Carter P. An efficient route to human bispecific IgG. Nat. Biotechnol. 16 (1998) 677-681
27. Milstein C., and Cuello A.C. Hybrid hybridomas and their use in immunohistochemistry. Nature 305 (1983) 537-540
28. Ridgway J.B., Presta L.G., and Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9 (1996) 617-621
29. Shen J., Vil M.D., Jimenez X., Iacolina M., Zhang H., and Zhu Z. Single variable domain-IgG fusion: a novel recombinant approach to fc domain-containing bispecific antibodies. J. Biol. Chem. 281 (2006) 10706-10714
30. Todorovska A., Roovers R.C., Dolezal O., Kortt A.A., Hoogenboom H.R., and Hudson P.J. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J. Immunol. Methods 248 (2001) 47-66
31. Zhu Z., Zapata G., Shalaby R., Snedecor B., Chen H., and Carter P. High level secretion of a humanized bispecific diabody from Escherichia coli. Biotechnology (N Y) 14 (1996) 192-196
32. Zuo Z., Jimenez X., Witte L., and Zhu Z. An efficient route to the production of an IgG-like bispecific antibody. Protein Eng. 13 (2000) 361-367